TYBOURNE CAPITAL MANAGEMENT (HK) LTD 13D and 13G filings for Zentalis Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 10:52 am Sale |
2022-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL |
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,231,427 3.900% |
-396,982 (-15.10%) |
Filing |
| 2022-02-14 12:06 pm Sale |
2021-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL |
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 5.800% |
-36,000 (-1.35%) |
Filing |
| 2020-05-29 09:21 am Purchase |
2020-05-29 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL |
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,664,409 7.400% |
2,664,409 (New Position) |
Filing |